Human Genome Sciences Inc., which was acquired for $3.6 billion by London-based GlaxoSmithKline Plc in August, intends to lay off 97 employees in mid-December, and an additional but unspecified number of cuts are planned for next year, the company warned Maryland labor regulators this week.
The Rockville-based biopharmaceuticals company, which employed as many as 1,000 people up until the acquisition, is in the process of integrating with GSK, a spokesman said.
Previously, the company disclosed in September it would cut 114 positions by the end of this month. A third round of cuts are planned for early next year, but the company did not disclose a precise figure to the Maryland Department of Labor, Licensing and Regulation, which tracks mass layoffs among employers in the state.
Distributed by MCT Information Services
Most Popular Stories
- SEO Traffic Lab Celebrate Wins at Digital Marketing Event 'Internet World 2013' in London
- Social Media Initiatives Should Follow Customers' Lead
- Apple CEO: Offshore Units Not a 'Tax Gimmick'
- U.S. Senate Accuses Apple of Large-scale Tax Avoidance
- UTEP Water Recycling Project Wins Venture Titles
- Marketo Makes a Mint in IPO: Stock Shoots Up More than 50 Percent
- Bieber Booed at Billboard Awards
- Crude Oil Up, Gasoline Down
- Austin Startup Compare Metrics Raises $3.5 Million for Expansion
- Why So Many Top 'Car Guys' Are Actually Women